The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

Published 2008 View Full Article

Authors

Keywords

Journal

BJU INTERNATIONAL

Volume 102, Issue 11, Pages 1531-1538

Publisher

Wiley

Online

2008-11-21

DOI

10.1111/j.1464-410x.2008.08183.x

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

BJU INTERNATIONAL

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.